United States Cardiovascular Surgery Devices Market Outlook to 2025 – Beating Heart Surgery Systems, Cardiopulmonary Bypass Equipment and Perfusion Disposables
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s “United States Cardiovascular Surgery Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Cardiovascular Surgery Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Beating Heart Surgery Systems, Cardiopulmonary Bypass Equipment and Perfusion Disposables.
The United States Cardiovascular Surgery Devices Market report provides key information and data on:
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2015 to 2025.
• 2019 company share and distribution share data for Cardiovascular Surgery Devices Market.
• Global corporate-level profiles of key companies operating within the United States Cardiovascular Surgery Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
United States Cardiovascular Surgery Devices is segmented as follows:
• Beating Heart Surgery Systems
• Cardiopulmonary Bypass Equipment
• Perfusion Disposables
Reasons to Buy
Key Reasons to Purchase – The United States Cardiovascular Surgery Devices Market report helps you to develop:
• Business strategies by identifying the key market segments poised for strong growth in the future.
• Market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.
• Medtronic Plc
• Terumo Medical Corp
• LivaNova PLC
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 What Is This Report About? 6
2.2 Cardiovascular Surgery Devices Market Segmentation 6
2.3 Definitions of Markets Covered in the Report 7
3 Cardiovascular Surgery Devices Market, United States 9
3.1 Cardiovascular Surgery Devices Market, United States, Revenue ($m), 2015-2025 9
3.1.1 Beating Heart Surgery Systems Market, United States, Revenue ($m), by Segment, 2015-2025 11
3.1.2 Perfusion Disposables Market, United States, Revenue ($m), by Segment, 2015-2025 13
3.2 Cardiovascular Surgery Devices Market, United States, Volume (Units), 2015-2025 15
3.2.1 Beating Heart Surgery Systems Market, United States, Volume (Units), by Segment, 2015-2025 17
3.2.2 Perfusion Disposables Market, United States, Volume (Units), by Segment, 2015-2025 19
3.3 Cardiovascular Surgery Devices Market, United States, Average Price ($), 2015-2025 21
3.4 Cardiovascular Surgery Devices Market, United States, Distribution Share by Revenue ($m), 2019 23
3.5 Cardiovascular Surgery Devices Market, United States, Company Share by Revenue ($m), 2019 24
4 Overview of Key Companies in United States, Cardiovascular Surgery Devices Market 26
4.1 Medtronic Plc 26
4.1.1 Company Overview 26
4.2 Terumo Medical Corp 26
4.2.1 Company Overview 26
4.3 LivaNova PLC 26
4.3.1 Company Overview 26
4.4 Maquet Holding BV & Co KG 27
4.4.1 Company Overview 27
5 Cardiovascular Surgery Devices Market Pipeline Products 28
6 Financial Deals Landscape 30
6.1 Acquisition 30
6.1.1 AtriCure to Acquire SentreHEART 30
6.2 Debt Offerings 32
6.2.1 CryoLife Prices Private Placement of
4.250% Notes Due 2025 for USD100 Million 32
6.2.2 Boston Scientific Raises USD1.2 Billion in Public Offering of
2.65% Senior Notes due 2030 34
6.2.3 Boston Scientific Raises USD500 Million in Public Offering of
1.9% Senior Notes due 2025 36
6.2.4 Integra LifeSciences Prices Private Placement of
0.5% Convertible Senior Notes Due 2025 for USD500 Million 38
6.2.5 Boston Scientific Raises USD999.2 Million in Public Offering of
0.625% Notes Due 2027 40
6.3 Equity Offerings 42
6.3.1 SurModics Plans to Raise up to USD200 Millon in Public Offering of Securities 42
6.3.2 Boston Scientific Raises USD1 Billion in Public Offering of Shares 43
6.3.3 Boston Scientific Raises USD1 Billion in Public Offering of
5.5% Mandatory Convertible Preferred Stock 45
6.3.4 Lemaitre Vascular Files Registration Statement for Public Offering of Securities for up to USD200 Million 47
6.3.5 SI-Bone Prices USD92.45 Million Public Offeirng of Shares 48
6.3.6 SI-Bone Plans to Raise up to USD200 Million in Public Offering of Securities 50
6.4 Venture Financing 51
6.4.1 NuPulseCV Raises USD2.1 Million in Venture Financing 51
6.4.2 Emboline Raises USD5 Million in Financing 52
6.4.3 Scinovia Raises Additional USD1 Million in Venture Financing 53
7 Recent Developments 54
7.1 Corporate Communications 54
7.1.1 Feb 03, 2020: Surmodics names Nusrath Sultana, MD, as Vice President, Clinical Affairs 54
7.1.2 Jan 31, 2020: Emboline completes $5m bridge round of financing 54
7.1.3 Dec 16, 2019: MiMedx Announces addition of Peter M. Carlson 55
7.1.4 Dec 06, 2019: Gilero opens new design center in Southern California 55
7.1.5 Dec 04, 2019: SI-BONE names Jeryl Hilleman to Board of Directors 56
7.1.6 Nov 26, 2019: MiMedx names William "Butch" Hulse as General Counsel and Secretary 56
7.1.7 Sep 20, 2019: MiMedx announces resignation of board member 57
7.1.8 Aug 19, 2019: Merit Medical announces appointment of Lynne N. Ward to its Board of Directors 57
7.1.9 Aug 13, 2019: SI-BONE: Departure of directors or certain officers 57
7.1.10 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 58
7.2 Financial Announcements 58
7.2.1 Feb 24, 2020: Merit Medical reports earnings for fourth quarter and year ended December 31, 2019, gives FY 2020 Guidance 58
7.2.2 Feb 19, 2020: Integra LifeSciences reports fourth quarter and full-year 2019 financial results and provides 2020 financial guidance 60
7.2.3 Feb 13, 2020: CryoLife reports fourth quarter and full year 2019 financial results 61
7.2.4 Feb 06, 2020: LeMaitre Vascular Announces Q4 2019 Financial Results 62
7.2.5 Feb 05, 2020: Boston Scientific announces results for fourth quarter and full year 2019 62
7.2.6 Feb 05, 2020: Surmodics reports first quarter Fiscal 2020 results 64
7.2.7 Jan 14, 2020: Boston Scientific announces preliminary unaudited sales for the fourth quarter and full year 2019 65
7.2.8 Jan 09, 2020: SI-BONE reports preliminary unaudited revenue for fourth quarter and full year 2019 and provides full year 2020 revenue guidance 66
7.2.9 Nov 11, 2019: SI-BONE reports third quarter 2019 financial results and updates full-year 2019 revenue guidance 67
7.2.10 Oct 31, 2019: Surmodics reports fourth quarter fiscal 2019 results and issues fiscal 2020 revenue and EPS Guidance 68
7.2.11 Oct 30, 2019: CryoLife reports third quarter 2019 financial results 68
7.2.12 Oct 30, 2019: Merit Medical reports earnings for third quarter of 2019 69
7.2.13 Oct 24, 2019: Integra LifeSciences reports third quarter 2019 financial results 72
7.2.14 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 73
7.2.15 Oct 23, 2019: Edwards Lifesciences reports third quarter results 75
7.2.16 Oct 23, 2019: LeMaitre Vascular announces Q3 2019 financial results 77
7.2.17 Aug 06, 2019: SI-BONE reports second quarter 2019 financial results 77
7.2.18 Jul 31, 2019: Surmodics reports third quarter fiscal 2019 results and raises fiscal 2019 revenue and EPS guidance 78
7.2.19 Jul 30, 2019: CryoLife reports second quarter 2019 financial results 79
7.2.20 Jul 25, 2019: Merit Medical reports earnings for second quarter of 2019 80
7.2.21 Jul 24, 2019: Integra LifeSciences reports second quarter 2019 financial results 82
7.2.22 Jul 24, 2019: LeMaitre Vascular announces Q2 2019 financial results 83
7.2.23 Jul 24, 2019: Boston Scientific announces results for second quarter 2019 83
7.2.24 Jul 23, 2019: Edwards Lifesciences reports second quarter results for the year 2019 85
7.3 Government and Public Interest 87
7.3.1 Jan 27, 2020: Merit Medical issues statement regarding director nominations from starboard 87
7.3.2 Aug 01, 2019: FRESH 3D printing used to rebuild functional components of human heart 87
7.4 Legal And Regulatory 88
7.4.1 Apr 06, 2020: MiMedx Group agrees to pay $6.5 million to resolve false claims act allegations of false commercial pricing disclosures 88
7.4.2 Nov 26, 2019: MiMedx announces Securities and Exchange Commission Settlement 89
7.4.3 Nov 26, 2019: SEC charges biotech company and executives with accounting fraud 89
7.4.4 Sep 30, 2019: Mallinckrodt finalizes settlement to resolve "Track 1" opioid cases with the Ohio Counties of Cuyahoga and Summit 90
7.4.5 Sep 06, 2019: Mallinckrodt announces settlement in principle to resolve "Track 1" opioid cases with the Ohio Counties of Cuyahoga and Summit 91
7.4.6 Sep 04, 2019: Faruqi & Faruqi Encourages Investors who suffered losses exceeding $50,000 in Mallinckrodt to contact the Firm 91
7.4.7 Sep 03, 2019: Mallinckrodt announces completion of previously disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor sales and marketing activities 92
7.5 Other Significant Developments 92
7.5.1 Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific 92
7.5.2 Apr 02, 2020: SI-BONE provides business update in response to covid-19 pandemic 93
7.5.3 Feb 28, 2020: Long Beach Medical Center only Southern California site participating in AFib clinical trial 93
7.5.4 Nov 04, 2019: Ernie Green Industries and Gilero announce business realignment 94
7.5.5 Oct 10, 2019: CINDE announces Edwards Lifesciences invests $100 million to expand its operations in Costa Rica 95
7.5.6 Sep 11, 2019: CryoLife enters into distribution agreement with Endospan 96
7.5.7 Aug 28, 2019: Boston Scientific Celebrates 15th Anniversary in Costa Rica 97
7.5.8 Aug 01, 2019: NIH Grant for Cardiothoracic Surgery Awarded 98
7.5.9 Jul 10, 2019: Medtronic announces the early results of its cash tender offers for up to $5.525 billion of certain outstanding debt securities 99
7.6 Strategy And Business Planning 100
7.6.1 Feb 11, 2020: Celerion expands clinical research to Nebraska Innovation Campus 100
7.6.2 Jan 15, 2020: Merit milestones: facilities in Galway and Tijuana reach 1,000 employees 100
7.6.3 Dec 06, 2019: Gilero opens new design center in Southern California 101
8 Appendix 102
8.1 Research Methodology 103
8.1.1 Coverage 103
8.1.2 Secondary Research 103
8.1.3 Primary Research 104
8.1.4 Market Modeling and Forecasting 105
8.1.5 Company Share Analysis 107
8.1.6 Distribution Share Analysis 107
8.1.7 Benchmarking 107
8.2 GlobalData Consulting 108
8.3 Contact Us 108
8.4 Disclaimer 109
Frequently asked questions
Undecided about purchasing this report?Enquire Before Buying
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.